乳铁蛋白与溶菌酶减少马拉维儿童环境性肠功能障碍与发育迟缓:随机对照试验研究方案
该研究为前瞻性随机安慰剂对照平行组试验,计划在马拉维农村12-23月龄儿童中每日补充乳铁蛋白与溶菌酶,评估其减少环境性肠功能障碍(EED)和发育迟缓的效果;干预组与对照组各计划纳入86名受试者,主要结局为基线至8周和16周尿中乳果糖排泄百分比(Δ%L)的变化,采用意向性治疗分析。
要点
- 研究对象为马拉维农村12-23月龄儿童,干预为每日补充乳铁蛋白与溶菌酶,对照为安慰剂。
- 主要结局为基线至8周和16周Δ%L的变化,采用意向性治疗分析。
- 干预组与对照组各计划纳入86名受试者,受试者、照护者及研究人员均设盲。
核心结论
- 将采用严格的临床试验设计评估乳铁蛋白与溶菌酶作为膳食补充剂用于EED高风险儿童的生物学合理性。
- 若被证明有效,这些安全的蛋白质可能显著减少儿童营养不良负担并改善生存。
研究设计与样本
- 前瞻性随机安慰剂对照平行组随机对照试验。
- 研究对象为马拉维农村12-23月龄儿童。
- 干预组与对照组各计划纳入86名受试者。
- 所有现场和实验室研究人员、受试者及其照护者均对分组设盲。
- 采用意向性治疗分析。
主要发现
- 原文为研究方案,尚未报告试验结果。
关键数值与推荐
- 主要结局为基线至8周和16周尿中乳果糖排泄百分比(Δ%L)的变化。
- EED的生物标志物为摄入乳果糖后4小时尿中排泄百分比(Δ%L)。
- 慢性营养不良(发育迟缓)以线性生长为测量指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic childhood malnutrition, as manifested by stunted linear growth, remains a persistent barrier to optimal child growth and societal development. Environmental enteric dysfunction (EED) is a significant underlying factor in the causal pathway to stunting, delayed cognitive development, and ultimately morbidity and mortality. Effective therapies against EED and stunting are lacking and further clinical trials are warranted to effectively identify and operationalize interventions. METHODS/DESIGN: A prospective randomized placebo-controlled parallel-group randomized controlled trial will be conducted to determine if a daily supplement of lactoferrin and lysozyme, two important proteins found in breast milk, can decrease the burden of EED and stunting in rural Malawian children aged 12-23 months old. The intervention and control groups will have a sample size of 86 subjects each. All field and laboratory researchers will be blinded to the assigned intervention group, as will the subjects and their caregivers. The percentage of ingested lactulose excreted in the urine (Δ%L) after 4 h will be used as the biomarker for EED and linear growth as the measure of chronic malnutrition (stunting). The primary outcomes of interest will be change in Δ%L from baseline to 8 weeks and to 16 weeks. Intention-to-treat analyses will be used. DISCUSSION: A rigorous clinical trial design will be used to assess the biologically plausible use of lactoferrin and lysozyme as dietary supplements for children at high risk for EED. If proven effective, these safe proteins may serve to markedly reduce the burden of childhood malnutrition and improve survival. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02925026 . Registered on 4 October 2016.
引用
- Cheng WD, Wold KJ, Benzoni NS, et al. Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29110675. doi:10.1186/s13063-017-2278-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。